Page last updated: 2024-12-07

indium arsenide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID91500
MeSH IDM0206362

Synonyms (25)

Synonym
einecs 215-115-3
indium arsenide (inas)
indium arsenide
indium monoarsenide
indiam arsenide
1303-11-3
indiganylidynearsane
NCGC00248086-01
dtxsid5023825 ,
tox21_300528
cas-1303-11-3
dtxcid503825
NCGC00254268-01
j1a23s0911 ,
unii-j1a23s0911
indium monoarsenide (inas)
indium arsenide [mi]
mfcd00016144
indium arsenide, 99% metals basis
indium arsenide, 99.9999% metals basis
indium arsenide, 99.99%metals basis
Q418583
indium arsenide powder
indium arsenide nanopowder
BAA30311

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" From the present study, the toxic potency of these particles was provisionally estimated to be in the following order: InAs > GaAs > As2O3, at the dosage level used in this study."( Comparative study of the toxic effects of gallium arsenide, indium arsenide and arsenic trioxide following intratracheal instillations to the lung of Syrian golden hamsters.
Gotoh, K; Hirata, M; Inoue, N; Makita, Y; Omura, M; Tanaka, A; Yamazaki, K; Zhao, M, 2000
)
0.55
" Although the increased use of these materials has raised concerns about occupational exposure to them, there is little information regarding the adverse health effects to workers arising from exposure to these particles."( Toxicity of indium arsenide, gallium arsenide, and aluminium gallium arsenide.
Tanaka, A, 2004
)
0.7
" In contrast to silicon, InAs forms an unstable oxide layer under ambient conditions, which can corrode over time and leach toxic indium and arsenic components."( Wet-chemical passivation of InAs: toward surfaces with high stability and low toxicity.
Ivanisevic, A; Jewett, SA, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" From the present study, the toxic potency of these particles was provisionally estimated to be in the following order: InAs > GaAs > As2O3, at the dosage level used in this study."( Comparative study of the toxic effects of gallium arsenide, indium arsenide and arsenic trioxide following intratracheal instillations to the lung of Syrian golden hamsters.
Gotoh, K; Hirata, M; Inoue, N; Makita, Y; Omura, M; Tanaka, A; Yamazaki, K; Zhao, M, 2000
)
0.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency68.58960.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency27.30600.000221.22318,912.5098AID743042
retinoid X nuclear receptor alphaHomo sapiens (human)Potency23.93390.000817.505159.3239AID1159527; AID1159531
estrogen nuclear receptor alphaHomo sapiens (human)Potency27.30600.000229.305416,493.5996AID743079
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (214)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (2.34)18.2507
2000's87 (40.65)29.6817
2010's109 (50.93)24.3611
2020's13 (6.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.64 (24.57)
Research Supply Index5.37 (2.92)
Research Growth Index5.81 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.40%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other211 (98.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]